9.415
price up icon0.59%   0.065
after-market Dopo l'orario di chiusura: 9.44 0.025 +0.27%
loading

Viatris Inc Borsa (VTRS) Ultime notizie

pulisher
03:14 AM

What drives Viatris Inc. stock priceMarket-crushing profits - PrintWeekIndia

03:14 AM
pulisher
Jul 24, 2025

Bausch Health adds two pharmaceutical industry veterans to board By Investing.com - Investing.com Nigeria

Jul 24, 2025
pulisher
Jul 24, 2025

Bausch Health Expands Leadership: Ex-Viatris CEO and Bristol Myers Legal Chief Join Board in Strategic Move - Stock Titan

Jul 24, 2025
pulisher
Jul 24, 2025

Novo Nordisk defeated in Wegovy patent dispute by Viatris - Yahoo Finance

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Viatris Inc. stockExponential wealth increase - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Viatris’ Wegovy Copy Sheds One Novo Patent in Delaware Lawsuit - Bloomberg Law News

Jul 23, 2025
pulisher
Jul 23, 2025

Covering The Flaws In The Viatris Undervaluation Argument (NASDAQ:VTRS) - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

What to Expect From Viatris' Next Quarterly Earnings Report - MSN

Jul 23, 2025
pulisher
Jul 22, 2025

What To Expect From Viatris' Next Quarterly Earnings Report - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Viatris Inc. a good long term investmentExplosive capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

VTRS Down on Late-Stage Study Failure of Eye Disease Drug - MSN

Jul 22, 2025
pulisher
Jul 21, 2025

Agree To Buy Viatris At $5, Earn 3% Using Options - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Viatris’ blepharitis ointment fails Phase III trial - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Viatris Phase III MR-139 trial in blepharitis misses goal - The Pharma Letter

Jul 21, 2025
pulisher
Jul 20, 2025

Viatris Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

Viatris Announces Disappointing Phase 3 Study Results for MR-139 in Blepharitis, But Continues to Focus on Delivering Novel Therapies. - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Viatris' Setback in Blepharitis Trial: A Harbinger or a Hurdle for Ophthalmic Innovation? - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Trend Tracker for (VTRS) - news.stocktradersdaily.com

Jul 19, 2025
pulisher
Jul 19, 2025

Viatris Inc. Stock Forecasts: Trial Miss Pressures Recovery of Core Business - AInvest

Jul 19, 2025
pulisher
Jul 18, 2025

Viatris stock unchanged as Goldman maintains Neutral rating on trial miss By Investing.com - Investing.com South Africa

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review - Benzinga

Jul 18, 2025
pulisher
Jul 18, 2025

Why Viatris (VTRS) Stock Is Falling Today - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris stock unchanged as Goldman maintains Neutral rating on trial miss - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Shares Dip After Blepharitis Treatment Fails to Hit Main Study Goal - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target - Barron's

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris' Resilience in Ophthalmology: Navigating Setbacks and Strategic Growth - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Why Is Viatris Stock Falling In Pre-market? - Nasdaq

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris stock down on late-stage trial setback (VTRS:NASDAQ) - Seeking Alpha

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris eye ointment fails late-stage study, shares fall - TradingView

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris stock falls after Phase 3 blepharitis study misses endpoint - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris blepharitis treatment fails to meet primary endpoint in trial - Investing.com India

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris eye therapy fails to meet late-stage trial goal - TradingView

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis - PR Newswire

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris (VTRS) Announces Positive Top-line Results from VEGA-3 - MSN

Jul 18, 2025
pulisher
Jul 17, 2025

Viatris (VTRS) Receives a Hold from Goldman Sachs - The Globe and Mail

Jul 17, 2025
pulisher
Jul 16, 2025

Hypopituitarism Treatment Market Expansion Supported - openPR.com

Jul 16, 2025
pulisher
Jul 16, 2025

Viatris: A Contrarian Bet with Minimal Downside Risk - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Viatris: A Contrarian Bet With Virtually No Downside (NASDAQ:VTRS) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 16, 2025

Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT - MSN

Jul 16, 2025
drug_manufacturers_specialty_generic RDY
$14.66
price down icon 0.31%
$132.16
price up icon 0.38%
$304.50
price down icon 0.57%
$14.93
price up icon 1.60%
$72.91
price up icon 2.79%
Capitalizzazione:     |  Volume (24 ore):